Accessibility Menu
PharmaCom BioVet logo

PharmaCom BioVet(OTC) PHMB

Current Price$0.00
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-100%
5 Year-99%
1 Year+0%
1 Month+0%
PharmaCom BioVet last closing stock price
MetricPriceDate
Last closeUSD 0.002025-11-10
PharmaCom BioVet stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002025-01-07
1 month+0%USD 0.002025-01-07
3 month+0%USD 0.002025-01-07
Year to date+0%USD 0.002024-12-24
1 year+0%USD 0.002024-11-08
3 year+0%USD 0.002022-11-11
5 year-99%USD 0.002020-11-09
Since inception-100%USD 0.072008-08-05

PharmaCom BioVet Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-1.47 (Low)

Price

$0.00

Volume

35,311,626

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

PHMB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PharmaCom BioVet

PharmaCom BioVet, Inc. is a specialized veterinary oncology company focused on advancing innovative cancer therapies for companion animals. Established in 1995, the company operates treatment centers across the United States, dedicated to improving the lives of pets diagnosed with cancer.

Products and Services
  • Bone marrow transplantation for companion animals
  • Innovative cancer therapies targeting lymphoma and other cancers
  • Proprietary medical devices and pharmaceutical compounds
Growth Outlook
  • Expansion of treatment centers expected to increase patient reach
  • Growing demand for veterinary oncology services in the U.S.
  • Focus on research and development to enhance treatment options
Financial Highlights
  • Market capitalization stands at approximately $1.08 million
  • Recent trading volume averages around 150,000 shares
  • Stock price has fluctuated between $0.000001 and $0.0001
PharmaCom BioVet, Inc. is positioned in a niche market with significant growth potential. The focus on veterinary oncology addresses an increasing need for specialized care in pets, particularly as pet ownership rises. The company's commitment to research and development aims to enhance treatment options, which could lead to improved patient outcomes and increased market share. With a modest market capitalization, PharmaCom BioVet presents an intriguing opportunity for investors interested in the healthcare sector, particularly in the veterinary field.
AI Generated • Jul 3, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Headquarters

Raleigh, NC 27609, US

PHMB Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

35.31M

Avg. Volume

0

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

PharmaCom BioVet Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAHNMid-Atlantic Home Health Network, Inc.
$0.11+0.00%
AMBDAmerican Mobile Dental Corp.
$0.00+0.00%
ARPCArem Pacific Corporation
$0.00+0.00%
CYDXCYduct Diagnostics, Inc.
$2.70+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About PHMB

What is the current price of PharmaCom BioVet?

PharmaCom BioVet is trading at $0.00 per share.

What is the 52-week range for PharmaCom BioVet?

Over the past 52 weeks, PharmaCom BioVet has traded between $0.00 and $0.00.

How much debt does PharmaCom BioVet have?

PharmaCom BioVet total debt is unavailable.

How much cash does PharmaCom BioVet have on hand?

PharmaCom BioVet does not have cash on hand data available.

What is PharmaCom BioVet’s dividend yield?

PharmaCom BioVet does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services